Abe Tatsuya, Kunimoto Masao, Hachiro Yoshikazu, Ohara Kei, Inagaki Mitsuhiro
Department of Proctology, Kunimoto Hospital, Asahikawa, Hokkaido, Japan.
Ann Coloproctol. 2022 Dec;38(6):403-408. doi: 10.3393/ac.2021.00248.0035. Epub 2021 Jul 21.
Perianal injection of bulking agents is an attractive treatment option for patients with mild to moderate fecal incontinence (FI). Various bulking agents have been used for injection therapy, but the optimal injection materials and methods are yet to be standardized. This study aimed to evaluate the effects of injection therapy using aluminum potassium sulfate and tannic acid (ALTA) in the management of FI.
This study included consecutive patients who underwent ALTA injection therapy for FI at our institution. The procedure was performed with the patient in the jackknife position, under caudal epidural anesthesia. The procedure consisted of a 4-step injection to the 3 main cushions and a multipoint injection to the remaining submucosa of the anal canal.
Seventy-seven patients (mean age, 76 years) were enrolled in the study. The mean Cleveland Clinic incontinence score of 11.9 ± 4.1 at baseline significantly improved to 7.3 ± 5.2 at 3 months following treatment. The mean maximal resting pressure also increased significantly 3 months after the intervention. Postoperative complications were observed in 3 patients (3.9%), and all events were mild. The mean duration of postoperative follow-up was 17.5 months. The cumulative recurrence-free rate at 3 years was 72.4%.
ALTA injection for FI is safe, easy to perform, and provides reasonable mid-term outcomes. Moreover, concomitant anorectal diseases that may be contraindicated by other injectable bulking agents could be treated simultaneously. Therefore, ALTA injection is a promising alternative in the absence of other injectable agents.
对于轻至中度大便失禁(FI)患者,肛周注射填充剂是一种有吸引力的治疗选择。多种填充剂已用于注射治疗,但最佳的注射材料和方法尚未标准化。本研究旨在评估使用硫酸铝钾和鞣酸(ALTA)进行注射治疗对FI的疗效。
本研究纳入了在我们机构接受ALTA注射治疗FI的连续患者。该操作在患者折刀位、骶管硬膜外麻醉下进行。操作包括对3个主要垫进行4步注射以及对肛管其余黏膜下层进行多点注射。
77例患者(平均年龄76岁)纳入研究。基线时平均克利夫兰诊所失禁评分为11.9±4.1,治疗后3个月显著改善至7.3±5.2。干预后3个月平均最大静息压力也显著增加。3例患者(3.9%)出现术后并发症,所有事件均为轻度。术后平均随访时间为17.5个月。3年时累积无复发率为72.4%。
ALTA注射治疗FI安全、易于实施,并能提供合理的中期结果。此外,对于其他可注射填充剂可能禁忌的伴发肛肠疾病可同时进行治疗。因此,在没有其他可注射剂的情况下,ALTA注射是一种有前景的替代方法。